Sitravatinib malate

Overview

Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC 50 s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl , MER , VEGFR3, VEGFR2, VEGFR1, KIT, FLT3 , DDR2 , DDR1 , TRKA , TRKB , respectively. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > Discoidin Domain Receptor | Products > Signaling Pathways > Trk Receptor

Product Information

• Catalog No.: HY-16961A
• CAS No.: 2244864-88-6
• Molecular Formula: C37H35F2N5O9S
• Molecular Weight: 763.76
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source